title: Historic, clinical, and prognostic features of epileptic encephalopathies caused by CDKL5 mutations.
abstract: Mutations within the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene are important causes of early-onset epileptic encephalopathies. We sought to determine the historic, clinical, and prognostic features of epilepsy secondary to CDKL5 mutations. We performed retrospective chart reviews of children at our institution with epilepsy and CDKL5 mutations. Six children were identified. One manifested a deletion in exons 10-15 of the CDKL5 gene, another manifested a single base-pair duplication in exon 3, and the rest manifested base-pair exchanges. The mean age of seizure onset was 1.8 months (range, 1-3 months). Although the majority (4/6, 67%) presented with partial-onset seizures, all children developed infantile spasms. All children demonstrated developmental delay and visual impairment. Although such mutations are X-linked, two children were boys. They did not present with more severe phenotypes than their female counterparts. Despite trials of antiepileptic drugs (mean, 5; range, 3-7), steroids/adrenocorticotropic hormone (4/6; 67%), and the ketogenic diet (6/6; 100%), all children manifested refractory seizures at last follow-up. Although no treatment eliminated seizures, topiramate, vigabatrin, and the ketogenic diet were most helpful at reducing seizure frequency.
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA. moseley.brian@mayo.edu
authors.forename: Brian D
authors.initials: BD
authors.lastname: Moseley
authors.forename: Radhika
authors.initials: R
authors.lastname: Dhamija
authors.forename: Elaine C
authors.initials: EC
authors.lastname: Wirrell
authors.forename: Katherine C
authors.initials: KC
authors.lastname: Nickels
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use; D004252:DNA Mutational Analysis; D002658:Developmental Disabilities / Q000235:genetics*; D055423:Diet, Ketogenic; D004828:Epilepsies, Partial / Q000178:diet therapy / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009154:Mutation; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D012189:Retrospective Studies; D012640:Seizures / Q000178:diet therapy / Q000188:drug therapy / Q000235:genetics*; D013036:Spasms, Infantile / Q000235:genetics*
chemical_list: D000927:Anticonvulsants; D017346:Protein Serine-Threonine Kinases; C114482:CDKL5 protein, human